Peptide and protein drug delivery to and into tumors: Challenges and solutions

Drug Discovery Today

Volumn 8, Issue 6, 2003, Pages 259-266

  Torchilin, Vladimir P ^a   Lukyanov, Anatoly N ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; ANGIOPEPTIN; ANTINEOPLASTIC AGENT; ANTINUCLEAR ANTIBODY; ANTINUCLEAR AUTOANTIBODY 1G3; ANTINUCLEAR AUTOANTIBODY 2C5; ASPARAGINASE; DAUNORUBICIN; DOXORUBICIN; DRUG CARRIER; ENDOSTATIN; IMMUNOLIPOSOME; IMMUNOTOXIN; MACROGOL; OCTREOTIDE; ONCOSPAR; PACLITAXEL; RAF PROTEIN; RAS PROTEIN; RITUXIMAB; SOMATOSTATIN DERIVATIVE; STYRENE MALEIC ANHYDRIDE COPOLYMER; TRANSACTIVATOR PROTEIN; TRASTUZUMAB; UNCLASSIFIED DRUG; VAPREOTIDE;

CANCER THERAPY; CONJUGATION; DRUG ACTIVITY; DRUG APPROVAL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG FORMULATION; DRUG MECHANISM; DRUG PENETRATION; DRUG RETENTION; DRUG TOLERABILITY; ENDOCYTOSIS; HUMAN; MACROMOLECULE; MICELLE; PEPTIDE SYNTHESIS; RETICULOENDOTHELIAL SYSTEM; REVIEW; SIGNAL TRANSDUCTION; TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; CELL MEMBRANE PERMEABILITY; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASMS; PEPTIDES; PROTEINS; TISSUE DISTRIBUTION;

EID: 0037443713     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(03)02623-0     Document Type: Review

References (80)

1. Froidevaux S., Eberle A.N. Somatostatin analogs and radiopeptides in cancer therapy. Biopolymers. 66:2002;161-183.
2. Figg W.D., et al. Inhibition of angiogenesis: treatment options for patients with metastatic prostate cancer. Invest. New Drugs. 20:2002;183-194.
3. Kerbel R., Folkman J. Clinical translation of angiogenesis inhibitors. Nat. Rev. Cancer. 2:2002;727-739.
4. Ballard C.E., et al. Recent developments in depsipeptide research. Curr. Med. Chem. 9:2002;471-498.
5. Asselin B.L. The three asparaginases. Comparative pharmacology and optimal use in childhood leukemia. Adv. Exp. Med. Biol. 457:1999;621-629.
6. Baselga J., Albanell J. Mechanism of action of anti-HER2 monoclonal antibodies. Ann. Oncol. 12:2001;S35-S41.
7. Harries M., Smith I. The development and clinical use of trastuzumab (Herceptin). Endocr.-Relat. Cancer. 9:2002;75-85.
8. Marshall H. Anti-CD20 antibody therapy is highly effective in the treatment of follicular lymphoma. Trends Immunol. 22:2001;183-184.
9. Langer R. Drug delivery and targeting. Nature. 392:1998;5-10.
10. Santini J.T. Jr, et al. A controlled-release microchip. Nature. 397:1999;335-338.
11. Buchwald H., Rohde T.D. Implantable pumps. Recent progress and anticipated future advances. ASAIO J. 38:1992;772-778.
12. Kohudic M.A. Advances in Controlled Delivery of Drugs. 1994;Technomic Publishing.
13. LaVan D.A., et al. Moving smaller in drug discovery and delivery. Nat. Rev. Drug Discov. 1:2002;77-84.
14. Torchilin V.P. Immobilized Enzymes in Medicine. 1991;Springer-Verlag.
15. Takakura Y., et al. Control of pharmaceutical properties of soybean trypsin inhibitor by conjugation with dextran. II: Biopharmaceutical and pharmacological properties. J. Pharm. Sci. 78:1989;219-222.
16. Harris J.M., et al. Pegylation: a novel process for modifying pharmacokinetics. Clin. Pharmacokinet. 40:2001;539-551.
17. Veronese F.M., Harris J.M. Introduction and overview of peptide and protein pegylation. Adv. Drug Deliv. Rev. 54:2002;453-456.
18. Roberts M.J., et al. Chemistry for peptide and protein PEGylation. Adv. Drug Deliv. Rev. 54:2002;459-476.
19. Abuchowski A., et al. Cancer therapy with chemically modified enzymes. I. Antitumor properties of polyethylene glycol-asparaginase conjugates. Cancer Biochem. Biophys. 7:1984;175-186.
20. Ettinger A.R. Pegaspargase (Oncaspar). J. Pediatr. Oncol. Nurs. 12:1995;46-48.
21. Holle L.M. Pegaspargase: an alternative? Ann. Pharmacother. 31:1997;616-624.
22. Youngster S., et al. Structure, biology, and therapeutic implications of pegylated interferon alpha-2b. Curr. Pharm. Des. 8:2002;2139-2157.
23. Bukowski R., et al. Pegylated interferon alfa-2b treatment for patients with solid tumors: a phase I/II study. J. Clin. Oncol. 20:2002;3841-3849.
24. Maeda H. SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. Adv. Drug Deliv. Rev. 46:2001;169-185.
25. Mu Y., et al. Bioconjugation of laminin peptide YIGSR with poly(styrene co-maleic acid) increases its antimetastatic effect on lung metastasis of B16-BL6 melanoma cells. Biochem. Biophys. Res. Commun. 255:1999;75-79.
26. Maeda H., et al. Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J. Control. Release. 74:2001;47-61.
27. Senior J.H. Fate and behavior of liposomes in vivo: a review of controlling factors. Crit. Rev. Ther. Drug Carrier Syst. 3:1987;123-193.
28. Lasic D.D., Papahadjopoulos D. Medical Applications of Liposomes. 1998;Elsevier.
29. Klibanov A.L., et al. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett. 268:1990;235-237.
30. Torchilin V.P., Trubetskoy V.S. Which polymers can make nanoparticulate drug carriers long-circulating? Adv. Drug Deliv. Rev. 16:1995;141-155.
31. Yuan F., et al. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res. 54:1994;3352-3356.
32. Gabizon A.A. Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest. 19:2001;424-436.
33. FDA approves DaunoXome as first-line therapy for Kaposi's sarcoma. J. Int. Assoc. Physicians AIDS Care. 2:1996;50-51.
34. Weissig V., et al. Accumulation of protein-loaded long-circulating micelles and liposomes in subcutaneous Lewis lung carcinoma in mice. Pharm. Res. 15:1998;1552-1556.
35. Hobbs S.K., et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc. Natl. Acad. Sci. U. S. A. 95:1998;4607-4612.
36. Trubetskoy V.S., Torchilin V.P. Use of polyoxyethylene-lipid conjugates as long-circulating carriers for delivery of therapeutic and diagnostic agents. Adv. Drug Deliv. Rev. 16:1995;311-320.
37. Gregoriadis G. Targeting of drugs. Nature. 265:1977;407-411.
38. Torchilin V.P. Handbook of Targeted Delivery of Imaging Agents. 1995;CRS Press.
39. Jurcic J.G., et al. Monoclonal antibody therapy of cancer. Cancer Chemother. Biol. Response Modif. 17:1997;195-216.
40. Dillman R.O. Monoclonal antibodies in the treatment of malignancy: basic concepts and recent developments. Cancer Invest. 19:2001;833-841.
41. Iakoubov L., et al. Anti-nuclear autoantibodies of the aged reactive against the surface of tumor but not normal cells. Immunol. Lett. 47:1995;147-149.
42. Iakoubov L.Z., Torchilin V.P. A novel class of antitumor antibodies: nucleosome-restricted antinuclear autoantibodies (ANA) from healthy aged nonautoimmune mice. Oncol. Res. 9:1997;439-446.
43. Iakoubov L.Z., Torchilin V.P. Nucleosome-releasing treatment makes surviving tumor cells better targets for nucleosome-specific anticancer antibodies. Cancer Detect. Prev. 22:1998;470-475.
44. Niv R., et al. Antibody engineering for targeted therapy of cancer: recombinant Fv- immunotoxins. Curr. Pharm. Biotechnol. 2:2001;19-46.
45. Vitetta E.S., et al. Immunotoxins: a new approach to cancer therapy. Science. 219:1983;644-650.
46. Park J.W., et al. Tumor targeting using anti-her2 immunoliposomes. J. Control. Release. 74:2001;95-113.
47. Gibbs J.B. Mechanism-based target identification and drug discovery in cancer research. Science. 287:2000;1969-1973.
48. Venter J.C., et al. The sequence of the human genome. Science. 291:2001;1304-1351.
49. Lander E.S., et al. Initial sequencing and analysis of the human genome. Nature. 409:2001;860-921.
50. Workman P. New drug targets for genomic cancer therapy: successes, limitations, opportunities and future challenges. Curr. Cancer Drug Targets. 1:2001;33-47.
51. Balmain A. Cancer genetics: from Boveri and Mendel to microarrays. Nat. Rev. Cancer. 1:2001;77-82.
52. Gibbs J.B., Oliff A. Pharmaceutical research in molecular oncology. Cell. 79:1994;193-198.
53. Sawyer T.K. Src homology-2 domains: structure, mechanisms, and drug discovery. Biopolymers. 47:1998;243-261.
54. Katz B.A. Structural and mechanistic determinants of affinity and specificity of ligands discovered or engineered by phage display. Annu. Rev. Biophys. Biomol. Struct. 26:1997;27-45.
55. Cortese R. Combinatorial Libraries: Synthesis, Screening and Application Potential. 1995;Walter de Gruyter, New York, USA.
56. Hussain S.P., et al. Tumor suppressor genes: at the crossroads of molecular carcinogenesis, molecular epidemiology and human risk assessment. Lung Cancer. 34:2001;S7-15.
57. Egleton R.D., Davis T.P. Bioavailability and transport of peptides and peptide drugs into the brain. Peptides. 18:1997;1431-1439.
58. Kamata H., et al. Amphiphilic peptides enhance the efficiency of liposome-mediated DNA transfection. Nucleic Acids Res. 22:1994;536-537.
59. Midoux P., et al. Membrane permeabilization and efficient gene transfer by a peptide containing several histidines. Bioconjug. Chem. 9:1998;260-267.
60. Mastrobattista E., et al. Functional characterization of an endosome-disruptive peptide and its application in cytosolic delivery of immunoliposome-entrapped proteins. J. Biol. Chem. 277:2002;27135-27143.
61. Lackey C.A., et al. A biomimetic pH-responsive polymer directs endosomal release and intracellular delivery of an endocytosed antibody complex. Bioconjug. Chem. 13:2002;996-1001.
62. Padilla De Jesus O.L., et al. Polyester dendritic systems for drug delivery applications: in vitro and in vivo evaluation. Bioconjug. Chem. 13:2002;453-461.
63. Vives E., et al. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J. Biol. Chem. 272:1997;16010-16017.
64. Wagner E. Application of membrane-active peptides for nonviral gene delivery. Adv. Drug Deliv. Rev. 38:1999;279-289.
65. Lewin M., et al. Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells. Nat. Biotechnol. 18:2000;410-414.
66. Bhorade R., et al. Macrocyclic chelators with paramagnetic cations are internalized into mammalian cells via a HIV-tat derived membrane translocation peptide. Bioconjug. Chem. 11:2000;301-305.
67. Torchilin V.P., et al. TAT peptide on the surface of liposomes affords their efficient intracellular delivery even at low temperature and in the presence of metabolic inhibitors. Proc. Natl. Acad. Sci. U. S. A. 98:2001;8786-8791.
68. Tseng Y.L., et al. Translocation of liposomes into cancer cells by cell-penetrating peptides penetratin and tat: a kinetic and efficacy study. Mol. Pharmacol. 62:2002;864-872.
69. Derossi D., et al. The third helix of the Antennapedia homeodomain translocates through biological membranes. J. Biol. Chem. 269:1994;10444-10450.
70. Elliott G., O'Hare P. Intercellular trafficking and protein delivery by a herpesvirus structural protein. Cell. 88:1997;223-233.
71. Frankel A.D., Pabo C.O. Cellular uptake of the tat protein from human immunodeficiency virus. Cell. 55:1988;1189-1193.
72. Mann D.A., Frankel A.D. Endocytosis and targeting of exogenous HIV-1 Tat protein. EMBO J. 10:1991;1733-1739.
73. Ho A., et al. Synthetic protein transduction domains: enhanced transduction potential in vitro and in vivo. Cancer Res. 61:2001;474-477.
74. Gius D.R., et al. Transduced p16INK4a peptides inhibit hypophosphorylation of the retinoblastoma protein and cell cycle progression prior to activation of Cdk2 complexes in late G1. Cancer Res. 59:1999;2577-2580.
75. Vocero-Akbani A., et al. Transduction of full-length Tat fusion proteins directly into mammalian cells: analysis of T cell receptor activation-induced cell death. Methods Enzymol. 322:2000;508-521.
76. Soga N., et al. Rho family GTPases regulate VEGF-stimulated endothelial cell motility. Exp. Cell Res. 269:2001;73-87.
77. Zezula J., et al. p21cip1 is required for the differentiation of oligodendrocytes independently of cell cycle withdrawal. EMBO Rep. 2:2001;27-34.
78. Hsia C.Y., et al. c-Rel regulation of the cell cycle in primary mouse B lymphocytes. Int. Immunol. 14:2002;905-916.
79. Schwarze S.R., et al. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science. 285:1999;1569-1572.
80. Richard J.P., et al. Cell-penetrating peptides. A reevaluation of the mechanism of cellular uptake. J. Biol. Chem. 278:2003;585-590.